CAD and hepatocellular carcinoma: In the present study, we found that circRAPGEF1 reprograms aspartate metabolism in HCC by downregulating ASS1 expression, resulting in the accumulation of intracellular aspartate levels and the subsequent activation of the S6K/CAD signaling pathway.